BMP activity controlled by BMPER regulates the proinflammatory phenotype of endothelium

Blood

Volumn 118, Issue 18, 2011, Pages 5040-5049

  Helbing, Thomas ^a   Rothweiler, René ^a   Ketterer, Elena ^a   Goetz, Lena ^a   Heinke, Jennifer ^a   Grundmann, Sebastian ^a   Duerschmied, Daniel ^a   Patterson, Cam ^b   Bode, Christoph ^a   Moser, Martin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CELL ADHESION MOLECULE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR 2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MALE; MICROSCOPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULITIS;

EID: 80855128771     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-339762     Document Type: Article

References (49)

1. Berk BC, Abe JI, Min W, Surapisitchat J, Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann N Y Acad Sci. 2001;947:93-109; discussion:109-111.
2. Kumar A, Lin Z, SenBanerjee S, Jain MK. Tumor necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-kappaB and histone deacetylases. Mol Cell Biol. 2005;25(14):5893-5903. (Pubitemid 40946546)
3. Parmar KM, Larman HB, Dai G, et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest. 2006;116(1):49-58. (Pubitemid 43121790)
4. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112(5):720-726. (Pubitemid 41099052)
5. SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004;199(10):1305-1315. (Pubitemid 38685723)
6. Kaminski A, Pohl CB, Sponholz C, et al. Upregulation of endothelial nitric oxide synthase inhibits pulmonary leukocyte migration following lung ischemia-reperfusion in mice. Am J Pathol. 2004;164(6):2241-2249. (Pubitemid 38669369)
7. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96(1):60-68.
8. Ouedraogo R, Gong Y, Berzins B, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via up-regulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 2007;117(6):1718-1726. (Pubitemid 46871356)
9. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88(11):4651-4655. (Pubitemid 21914599)
10. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8(11):857-869. (Pubitemid 47622560)
11. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91(4):1800-1809. (Pubitemid 23127387)
12. Csiszar A, Labinskyy N, Smith KE, et al. Down-regulation of bone morphogenetic protein 4 expression in coronary arterial endothelial cells: role of shear stress and the cAMP/protein kinase A pathway. Arterioscler Thromb Vasc Biol. 2007;27(4):776-782. (Pubitemid 46606706)
13. Zhang M, Zhou SH, Li XP, et al. Atorvastatin down-regulates BMP-2 expression induced by oxidized low-density lipoprotein in human umbilical vein endothelial cells. Circ J. 2008;72(5):807-812. (Pubitemid 351716687)
14. Heinke J, Wehofsits L, Zhou Q, et al. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res. 2008;103(8):804-812.
15. Csiszar A, Lehoux S, Ungvari Z. Hemodynamic forces, vascular oxidative stress, and regulation of BMP-2/4 expression. Antioxid Redox Signal. 2009;11(7):1683-1697.
16. Csiszar A, Labinskyy N, Jo H, Ballabh P, Ungvari Z. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. Am J Physiol Heart Circ Physiol. 2008;295(2):H569-577.
17. Csiszar A, Ahmad M, Smith KE, et al. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol. 2006;168(2):629-638. (Pubitemid 43271160)
18. Miriyala S, Gongora Nieto MC, Mingone C, et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation. 2006;113(24):2818-2825. (Pubitemid 44305294)
19. Moser M, Binder O, Wu Y, et al. BMPER, a novel endothelial cell precursor-derived protein, antagonizes bone morphogenetic protein signaling and endothelial cell differentiation. Mol Cell Biol. 2003;23(16):5664-5679. (Pubitemid 36951331)
20. Binnerts ME, Wen X, Cante-Barrett K, et al. Human Crossveinless-2 is a novel inhibitor of bone morphogenetic proteins. Biochem Biophys Res Commun. 2004;315(2):272-280. (Pubitemid 38183104)
21. Moser M, Yu Q, Bode C, Xiong JW, Patterson C. BMPER is a conserved regulator of hematopoietic and vascular development in zebrafish. J Mol Cell Cardiol. 2007;43(3):243-253. (Pubitemid 47304444)
22. Conley CA, Silburn R, Singer MA, et al. Cross-veinless 2 contains cysteine-rich domains and is required for high levels of BMP-like activity during the formation of the cross veins in Drosophila. Development. 2000;127(18):3947-3959.
23. Ikeya M, Kawada M, Kiyonari H, et al. Essential pro-Bmp roles of crossveinless 2 in mouse organogenesis. Development. 2006;133(22):4463-4473. (Pubitemid 46017821)
24. Harada K, Ogai A, Takahashi T, Kitakaze M, Matsubara H, Oh H. Crossveinless-2 controls bone morphogenetic protein signaling during early cardiomyocyte differentiation in P19 cells. J Biol Chem. 2008;283(39):26705- 26713.
25. Zhang JL, Qiu LY, Kotzsch A, et al. Crystal structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding. Dev Cell. 2008;14(5):739-750. (Pubitemid 351622617)
26. Serpe M, Umulis D, Ralston A, et al. The BMP-binding protein Crossveinless 2 is a short-range, concentration-dependent, biphasic modulator of BMP signaling in Drosophila. Dev Cell. 2008;14(6):940-953. (Pubitemid 351757202)
27. Helbing T, Rothweiler R, Heinke J, et al. BMPER is up-regulated by statins and modulates endothelial inflammation by intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol. 2010;30(3):554-560.
28. Helbing T, Volkmar F, Goebel U, et al. Kruppel-like factor 15 regulates BMPER in endothelial cells. Cardiovasc Res. 2010;85(3):551-559.
29. Zakin L, Metzinger CA, Chang EY, Coffinier C, De Robertis EM. Development of the vertebral morphogenetic field in the mouse: interactions between Crossveinless-2 and Twisted Gastrulation. Dev Biol. 2008;323(1):6-18.
30. Boergermann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol. 2010;42(11):1802-1807.
31. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4(1):33-41. (Pubitemid 350273653)
32. Hao J, Daleo MA, Murphy CK, et al. Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS One. 2008;3(8):e2904.
33. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation. 2005;111(18):2364-2372. (Pubitemid 40655331)
34. Kelley R, Ren R, Pi X, et al. A concentration-dependent endocytic trap and sink mechanism converts Bmper from an activator to an inhibitor of Bmp signaling. J Cell Biol. 2009;184(4):597-609.
35. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399(6736):597- 601.
36. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399(6736):601-605.
37. Groppe J, Greenwald J, Wiater E, et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature. 2002;420(6916):636-642. (Pubitemid 36764490)
38. Miyazono K, Miyazawa K. Id: a target of BMP signaling. Sci STKE. 2002;2002(151):pe40.
39. ten Dijke P, Korchynskyi O, Valdimarsdottir G, Goumans MJ. Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol. 2003; 211(1-2):105-113. (Pubitemid 37491242)
40. Ota T, Fujii M, Sugizaki T, et al. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol. 2002;193(3):299-318. (Pubitemid 35265950)
41. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109(21 Suppl 1):II27-33. (Pubitemid 38724153)
42. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res. 2007;101(3):234-247. (Pubitemid 47344073)
43. Libby P, Aikawa M, Jain MK. Vascular endothelium and atherosclerosis. Handb Exp Pharmacol. 2006;(176 Pt 2):285-306.
44. Sorescu GP, Song H, Tressel SL, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95(8):773-779. (Pubitemid 39390579)
45. Chang K, Weiss D, Suo J, et al. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. Circulation. 2007;116(11):1258-1266. (Pubitemid 47517537)
46. Kuo CT, Veselits ML, Barton KP, Lu MM, Clendenin C, Leiden JM. The LKLF transcription factor is required for normal tunica media formation and blood vessel stabilization during murine embryogenesis. Genes Dev. 1997;11(22):2996-3006. (Pubitemid 27508510)
47. Wani MA, Means RT Jr, Lingrel JB. Loss of LKLF function results in embryonic lethality in mice. Transgenic Res. 1998;7(4):229-238. (Pubitemid 28541847)
48. Atkins GB, Wang Y, Mahabeleshwar GH, et al. Hemizygous deficiency of Kruppel-like factor 2 augments experimental atherosclerosis. Circ Res. 2008;103(7):690-693.
49. Yao Y, Bennett BJ, Wang X, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010;107(4):485-494.